{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:35:24Z","timestamp":1791326124220,"version":"4.3.1"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pharmacist-led interventions are increasingly integrated into hematology-oncology care to address complex pharmacotherapy and medication safety challenges. However, their impact within hematological malignancies has not been comprehensively synthesized across clinical, process-related, and economic domains.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review was conducted to evaluate pharmacist-led interventions in patients with hematological malignancies across inpatient and outpatient settings. Thirty-three studies were included. Owing to substantial heterogeneity in study design, interventions, and outcome definitions, a structured qualitative synthesis was performed, with findings grouped by clinical, process-related, and economic outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirty-three studies were included, reporting clinical (\n                      <jats:italic>n<\/jats:italic>\n                      = 24), process-related (\n                      <jats:italic>n<\/jats:italic>\n                      = 23), and economic outcomes (\n                      <jats:italic>n<\/jats:italic>\n                      = 8). Pharmacist-led interventions most consistently improved medication management processes, including identification and resolution of drug-related problems, drug interaction management, and care coordination, with high acceptance rates of pharmacist recommendations. Several studies also reported improvements in medication adherence, toxicity management, and selected patient-reported outcomes; however, findings for disease response, survival, and hospitalization were heterogeneous and not consistently statistically significant. Economic evaluations were limited but suggested potential cost savings and favorable returns on investment associated with pharmacist involvement.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pharmacist-led interventions in hematology-oncology care improve medication management processes and may contribute to better adherence and medication safety. However, evidence for effects on clinical and economic outcomes remains limited and heterogeneous, highlighting the need for well-designed prospective studies using standardized outcome measures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420251147239<\/jats:ext-link>\n                      , identifier CRD420251147239.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1779201","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T05:33:40Z","timestamp":1776749620000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacist-led interventions in hematological malignancies: a systematic review of clinical, process and economic outcomes"],"prefix":"10.3389","volume":"17","author":[{"given":"Amna","family":"Mohamed","sequence":"first","affiliation":[{"name":"Pharmacy Department, College of Applied Sciences and Pharmacy, University of Technology and Applied Sciences","place":["Muscat, Oman"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bushra","family":"Salman","sequence":"additional","affiliation":[{"name":"Pharmacy Department, National Hematology and Bone Marrow Transplant Center, University Medical City","place":["Muscat, Oman"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raya","family":"Al Maskari","sequence":"additional","affiliation":[{"name":"Pharmacology & Clinical Pharmacy Department, College of Medicine and Health Sciences, Sultan Qaboos University","place":["Muscat, Oman"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalil","family":"Al-Farsi","sequence":"additional","affiliation":[{"name":"Hematology Department, National Hematology and Bone Marrow Transplant Center, University Medical City","place":["Muscat, Oman"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Yassin","sequence":"additional","affiliation":[{"name":"College of Medicine, Qatar University","place":["Doha, Qatar"]},{"name":"National Center for Cancer Care and Research, Hamad Medical Corporation","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1186\/s12885-024-12291-w","article-title":"Determination of drug-related problems in the hematology service: a prospective interventional study","volume":"24","author":"Albayrak","year":"2024","journal-title":"BMC CANCER"},{"key":"B2","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1177\/1078155220934167","article-title":"Incorporating a clinical oncology pharmacist into an ambulatory care pharmacy in pediatric hematology-oncology and transplant clinic: assessment and significance","volume":"27","author":"Ali","year":"2021","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B3","doi-asserted-by":"publisher","first-page":"10781552241265280","DOI":"10.1177\/10781552241265280","article-title":"Oncology stewardship practice in the United States: a hematology\/oncology pharmacy association national survey","volume":"31","author":"Banez","year":"2024","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B4","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2991\/chi.d.191101.001","article-title":"Moving toward continuous therapy in multiple myeloma","volume":"1","author":"Bonello","year":"2019","journal-title":"Clin. Hematol. Int."},{"key":"B5","volume-title":"Outcomes of chronic myelogenous leukemia and adherence to imatinib therapy (CML-AIT) study. Abstract# 60; platform category A2","author":"Campbell","year":"2012"},{"key":"B6","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1177\/1078155219875806","article-title":"Clinical and economic impact of clinical pharmacist intervention in a hematology unit","volume":"26","author":"Chen","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B7","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/ajhp\/zxz036","article-title":"Instilling value, quality, and safety through hematology and oncology stewardship","volume":"76","author":"Chung","year":"2019","journal-title":"Am. J. Health Syst. Pharm."},{"key":"B8","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/jcpt.12562","article-title":"The effects of pharmacist interventions on adult outpatients with cancer: a systematic review","volume":"42","author":"Colombo","year":"2017","journal-title":"J. Clin. Pharm. Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"10781552251324522","DOI":"10.1177\/10781552251324522","article-title":"Evaluating the impact of a pharmacist-led venetoclax ramp-up clinic for chronic lymphocytic leukemia patients: a retrospective chart review","author":"de Boer","year":"2025","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1177\/1078155220915763","article-title":"Clinical and economic impact of pharmacist interventions in an ambulatory hematology\u2013oncology department","volume":"26","author":"de Gr\u00e9gori","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.3390\/cancers14102532","article-title":"Clinical and economic impact of a multidisciplinary Follow-Up program in lymphoma patients","volume":"14","author":"Devaux","year":"2022","journal-title":"CANCERS"},{"key":"B12","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1590\/S1679-45082016AO3667","article-title":"Implementing a clinical pharmacy service in hematology","volume":"14","author":"Farias","year":"2016","journal-title":"Einstein Sao Paulo Braz"},{"key":"B13","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.sapharm.2024.02.006","article-title":"Impact of pharmacist-led interventions on medication-related problems among patients treated for cancer: a systematic review and meta-analysis of randomized control trials","volume":"20","author":"Fentie","year":"2025","journal-title":"Res. Soc. Adm. Pharm."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1177\/1078155220975088","article-title":"Impact of the implementation of a pharmacist-driven immunosuppression drug monitoring protocol for hematopoietic stem cell transplant recipients","volume":"27","author":"Gawedzki","year":"2021","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B15","doi-asserted-by":"publisher","first-page":"102141","DOI":"10.1016\/j.japh.2024.102141","article-title":"Establishment of a clinical pharmacist-led multiple myeloma clinic with collaborative prescribing model at the national center for cancer care and research in Qatar","volume":"64","author":"Ghasoub","year":"2024","journal-title":"J. Am. Pharm. Assoc."},{"key":"B16","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1007\/s13187-025-02584-4","article-title":"Improving pediatric oncology knowledge through pharmaceutical health education","volume":"40","author":"Gon\u00e7alves","year":"2025","journal-title":"J. Cancer Educ."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e1230","DOI":"10.1002\/cl2.1230","article-title":"PRISMA2020: an R package and shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and open synthesis campbell systematic reviews","volume":"18","author":"Haddaway","year":"2022","journal-title":"Campbell Syst. Rev."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e2500180","DOI":"10.1200\/OA-25-00180","article-title":"Strengthening supportive care: leveraging the expanding role of oncology pharmacists","volume":"2","author":"Hernandez","year":"2025","journal-title":"JCO Oncol. Adv."},{"key":"B19","doi-asserted-by":"publisher","first-page":"180","DOI":"10.29173\/jchla29801","article-title":"JBI critical appraisal checklist for systematic reviews and research syntheses","volume":"45","author":"Hilton","year":"2024","journal-title":"J. Can. Health Libr. Assoc."},{"key":"B20","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13045-021-01077-3","article-title":"Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting","volume":"14","author":"Hou","year":"2021","journal-title":"J. Hematol. OncolJ Hematol. Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e0263672","DOI":"10.1371\/journal.pone.0263672","article-title":"Incurable but treatable: understanding, uncertainty and impact in chronic blood cancers\u2014A qualitative study from the UK\u2019s haematological malignancy research network","volume":"17","author":"Howell","year":"2022","journal-title":"PLOS ONE"},{"key":"B22","unstructured":"Joanna briggs institute 2017 critical appraisal checklist for case control studies. Case control stud 2017"},{"key":"B23","unstructured":"Joanna briggs institute 2017 critical appraisal checklist for cohort studies"},{"key":"B24","unstructured":"Joanna briggs institute 2017 critical appraisal checklist for analytical cross sectional studies"},{"key":"B25","unstructured":"Joanna briggs institute 2017 critical appraisal checklist for economic evaluations 2017"},{"key":"B26","unstructured":"Joanna briggs institute 2020 critical appraisal checklist for randomized controlled trials"},{"key":"B27","unstructured":"Joanna briggs institute 2020 critical appraisal checklist for quasi-experimental studies (non-randomized experimental studies)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e1494","DOI":"10.1200\/OP.22.00056","article-title":"Financial toxicity intervention improves outcomes in patients with hematologic malignancy","volume":"18","author":"Knight","year":"2022","journal-title":"JCO Oncol. Pract."},{"key":"B29","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1177\/1078155215608523","article-title":"Impact of oncology pharmacist-managed oral anticancer therapy in patients with chronic myelogenous leukemia","volume":"22","author":"Lam","year":"2016","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B30","doi-asserted-by":"publisher","first-page":"565","DOI":"10.3390\/ph18040565","article-title":"Oncoral Follow-Up for outpatients treated with oral anticancer drugs assessed by relative dose intensity","volume":"18","author":"Larbre","year":"2025","journal-title":"Pharmaceuticals"},{"key":"B31","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1177\/1078155217690923","article-title":"Evaluation of a medication intensity screening tool used in malignant hematology and bone marrow transplant services to identify patients at risk for medication-related problems","volume":"24","author":"Lucena","year":"2018","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e324","DOI":"10.1200\/JOP.17.00039","article-title":"Improved adherence rates and clinical outcomes of an integrated, closed-loop, pharmacist-led oral chemotherapy management program","volume":"14","author":"Muluneh","year":"2018","journal-title":"J. Oncol. Pract."},{"key":"B33","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.pharma.2024.05.001","article-title":"Comprehensive medication management (CMM): application of a new pharmaceutical practice in onco-hematology","volume":"82","author":"Mansour","year":"2024","journal-title":"Ann. Pharm. Fr."},{"key":"B34","doi-asserted-by":"publisher","first-page":"6330","DOI":"10.3390\/curroncol30070467","article-title":"Toxicity profile of chimeric antigen receptor T-Cell and bispecific antibody therapies in multiple myeloma: pathogenesis, prevention and management","volume":"30","author":"Markouli","year":"2023","journal-title":"Curr. Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.18553\/jmcp.2019.25.11.1244","article-title":"Effect of a smart pill bottle and pharmacist intervention on medication adherence in patients with multiple myeloma new to lenalidomide therapy","volume":"25","author":"Mauro","year":"2019","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"B36","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1177\/10775587231186720","article-title":"A systematic review of outcomes related to nurse practitioner-delivered primary care for multiple chronic conditions","volume":"80","author":"McMenamin","year":"2023","journal-title":"Med. Care Res. Rev. MCRR"},{"key":"B37","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s00520-016-3486-6","article-title":"The role of clinical pharmacists in treatment adherence: fast impact in suppression of chronic myeloid leukemia development and symptoms","volume":"25","author":"Moulin","year":"2017","journal-title":"Support Care Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.11124\/JBISRIR-D-19-00099","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool","volume":"18","author":"Munn","year":"2019","journal-title":"JBI Database Syst. Rev. Implement Rep."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1177\/10781552221122034","article-title":"Impact of oral chemotherapy pharmacists on cost avoidance of oral oncolytics in an integrated health system","volume":"29","author":"Nguyen","year":"2023","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1007\/978-3-319-64263-5_49","article-title":"Prevention of infections in patients with hematological malignancies","author":"Nucci","year":"2017","journal-title":"Neoplast. Dis. Blood"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1007\/s00277-022-04872-1","article-title":"Oncology stewardship in acute myeloid leukemia","volume":"101","author":"Ochs","year":"2022","journal-title":"Ann. Hematol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.pharma.2016.03.007","article-title":"Impact of pharmaceutical intervention on quality of life and coping strategies in patients with haematological malignancies","volume":"74","author":"Opsomer","year":"2016","journal-title":"Ann. Pharm. Fr."},{"key":"B43","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e0243309","DOI":"10.1371\/journal.pone.0243309","article-title":"Immunomodulatory drugs in multiple myeloma: impact of the SCARMET (self CARe and MEdication toxicity) educational intervention on outpatients\u2019 knowledge to manage adverse effects","volume":"15","author":"P\u00e9richou","year":"2020","journal-title":"PloS One"},{"key":"B45","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1177\/1078155208093929","article-title":"Pharmaceutical care in an inpatient pediatric hematopoietic stem cell transplant service","volume":"14","author":"Prot-Labarthe","year":"2008","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.pharma.2025.07.005","article-title":"Oncology pharmacy practice: key insights, challenges, and perspectives \u2013 a position paper from the French society for oncology pharmacy (SFPO)","volume":"83","author":"Ranchon","year":"2025","journal-title":"Ann. Pharm. Fr."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1007\/s11096-020-01090-5","article-title":"Pharmacist review of high-risk haematology outpatients to improve appropriateness of antifungal prophylaxis","volume":"42","author":"Reslan","year":"2020","journal-title":"Int. J. Clin. Pharm."},{"key":"B48","doi-asserted-by":"publisher","first-page":"10781552251372492","DOI":"10.1177\/10781552251372492","article-title":"Oncology stewardship: a narrative review of principles and practices","author":"Salman","year":"2025","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1177\/1078155218759184","article-title":"Using a treatment diary to improve the medication adherence in patients with chronic myeloid leukaemia","volume":"25","author":"Santoleri","year":"2019","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B50","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.6004\/jnccn.2010.0127","article-title":"NCCN task force report: specialty pharmacy","volume":"8","author":"Schwartz","year":"2010","journal-title":"J. Natl. Compr. Cancer Netw. JNCCN"},{"key":"B51","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1177\/10781552231154465","article-title":"Oncology stewardship: role of the pharmacists for contribution in low and middle-income countries","volume":"29","author":"Siddiqui","year":"2023","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B52","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3390\/cancers14010087","article-title":"FDA-approved drugs for hematological malignancies\u2014the last decade review","volume":"14","author":"Sochacka-\u0106wik\u0142a","year":"2021","journal-title":"Cancers"},{"key":"B53","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s11912-023-01482-6","article-title":"Chronic lymphocytic leukemia: time-limited therapy in the first-line setting and role of minimal residual disease","volume":"26","author":"Stumpf","year":"2024","journal-title":"Curr. Oncol. Rep."},{"key":"B54","doi-asserted-by":"publisher","first-page":"e674","DOI":"10.1200\/JOP.18.00085","article-title":"Collaborative physician-Pharmacist\u2013Managed multiple myeloma clinic improves guideline adherence and prevents treatment delays","volume":"14","author":"Sweiss","year":"2018","journal-title":"J. Oncol. Pract."},{"key":"B55","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1177\/1078155219851550","article-title":"Polypharmacy and potentially inappropriate medication use is highly prevalent in multiple myeloma patients and is improved by a collaborative physician\u2013pharmacist clinic","volume":"26","author":"Sweiss","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B56","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1182\/hematology.2021000232","article-title":"Upfront therapy: the case for continuous treatment","volume":"2021","author":"Tam","year":"2021","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1177\/1078155220964539","article-title":"Acceptability of pharmacist-led interventions to resolve drug-related problems in patients with chronic myeloid leukaemia","volume":"27","author":"Tan","year":"2021","journal-title":"J. Oncol. Pharm. Pract. Off. Publ. Int. Soc. Oncol. Pharm. Pract."},{"key":"B58","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41392-023-01521-5","article-title":"Immunotherapy in hematologic malignancies: achievements, challenges and future prospects","volume":"8","author":"Tang","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"key":"B59","doi-asserted-by":"publisher","first-page":"e543","DOI":"10.1016\/j.clml.2020.04.012","article-title":"Impact of an oncology clinical pharmacist specialist in an outpatient multiple myeloma clinic","volume":"20","author":"Virani","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"B60","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1177\/1078155220916516","article-title":"Evaluation and optimization of a clinical pharmacist driven transitions of care model for malignant hematology","volume":"27","author":"Wind","year":"2021","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B61","doi-asserted-by":"publisher","first-page":"253","DOI":"10.18553\/jmcp.2025.31.3.253","article-title":"Integrated health system pharmacy role in adherence, persistence, and adverse effect management for oral chronic lymphocytic leukemia therapy","volume":"31","author":"Wyatt","year":"2025","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"B62","doi-asserted-by":"publisher","first-page":"riaf098","DOI":"10.1093\/ijpp\/riaf098","article-title":"Impact of pharmacist-led interventions on oncology drug therapy outcomes: a systematic review and meta-analysis","volume":"34","author":"Xiang","year":"2025","journal-title":"Int. J. Pharm. Pract."},{"key":"B63","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1177\/10781552211073797","article-title":"Impact of the insertion of the clinical pharmacist in the allogeneic hematopoietic stem cells transplantation team","volume":"29","author":"Zanetti","year":"2023","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1007\/s00277-020-04045-y","article-title":"Improved time to treatment failure and survival in ibrutinib-treated malignancies with a pharmaceutical care program: an observational cohort study","volume":"99","author":"Zerbit","year":"2020","journal-title":"Ann. Hematol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"e13753","DOI":"10.1111\/ecc.13753","article-title":"Pharmaceutical cancer care for haematology patients on oral anticancer drugs: findings from an economic, clinical and organisational analysis","volume":"31","author":"Zerbit","year":"2022","journal-title":"Eur. J. Cancer Care (Engl)"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1779201\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T05:33:44Z","timestamp":1776749624000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1779201\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":65,"alternative-id":["10.3389\/fphar.2026.1779201"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1779201","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"article-number":"1779201"}}